Intellia Therapeutics, Inc. NTLA
Set alert
At close · Oct 30
After hours · Oct 30, 7:55 PM ET
- YTD
- +38.71%
- 1 year
- +1.63%
- Open
- 12.82
- Prev close
- 13.23
- Mkt cap
- 1.75B
- Vol
- 4.09M
- Avg vol
- 4.36M
- EPS
- -3.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.04
- High
- 13.13
- Forward P/E
- -4.86
- Beta
- 1.80
- Short ratio
- 7.63
- Inst. own
- 100.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 12.23
- 200-d avg
- 13.08
- 1y target
- 23.11
5D chart
Signals (110)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:50 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:20 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:50 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
3 days ago globenewswire.com
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
4 days ago globenewswire.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
1 week ago defenseworld.net
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey
Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast…
1 week ago zacks.com
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
2 weeks ago globenewswire.com
Intellia Therapeutics Appoints Jing L. Marantz, M.D.
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
2 weeks ago defenseworld.net
Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and United Therapeutics (NASDAQ: UTHR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…
3 weeks ago zacks.com
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…
3 weeks ago benzinga.com
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.
3 weeks ago defenseworld.net
Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at Barclays
Barclays assumed coverage on shares of Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set an "underweight" rating…
3 weeks ago benzinga.com
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
-
3 weeks ago benzinga.com
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8
Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.
3 weeks ago benzinga.com
Intellia Therapeutics Q2 2026 Earnings Call Transcript
Intellia Therapeutics (NASDAQ:NTLA) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to…
1 month ago globenewswire.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago defenseworld.net
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) vs. Bicycle Therapeutics (NASDAQ:BCYC)
Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
1 month ago marketbeat.com
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in…
1 month ago zacks.com
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
1 month ago defenseworld.net
Intellia Therapeutics (NASDAQ:NTLA) Stock Crosses Below Fifty Day Moving Average – What’s Next?
Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) shares passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $12.10 and…
1 month ago seekingalpha.com
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago zacks.com
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
-
1 month ago benzinga.com
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
-
1 month ago benzinga.com
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.
1 month ago zacks.com
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
-
1 month ago benzinga.com
Intellia Therapeutics Announces FDA Acceptance For Its Biologics License Application For Ionvo-Z; FDA Sets March 10, 2027, As PDUFA Date
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the…
1 month ago globenewswire.com
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world's first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved…
1 month ago defenseworld.net
Public Employees Retirement System of Ohio Invests $1.49 Million in Intellia Therapeutics, Inc. $NTLA
Public Employees Retirement System of Ohio acquired a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) during the undefined quarter, according to its most recent 13F filing with the…
1 month ago globenewswire.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
-
1 month ago benzinga.com
Intellia Therapeutics Enters Into $400M Non-Dilutive Senior Secured Term Loan Facility With OrbiMed
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it…
1 month ago globenewswire.com
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an…
1 month ago benzinga.com
Cathie Wood Trims 40K Shopify Shares After August Rally: Where ARK Is Reinvesting?
Cathie Wood's ARK sold 40,392 Shopify shares after a 25% August rally. Here's what ARKK and ARKW are betting on next.
3 months ago benzinga.com
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pharmaceuticals. See what other analysts say.
3 months ago benzinga.com
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.
4 months ago benzinga.com
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)
Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpark.
4 months ago benzinga.com
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% after beating earnings & revenue estimates. Other big gainers included QURE, CLPT, JLHL, BRAI, LZB,…
5 months ago benzinga.com
Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts updated their ratings on top companies. For full list of changes, including upgrades/downgrades, see our analyst ratings page.
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
6 months ago benzinga.com
Robinhood Posts Downbeat Q1 Results, Joins Enphase Energy, Avis Budget And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures up, Nasdaq 100 gains 100 points. Robinhood shares fall 10.7% after reporting lower-than-expected Q1 results. O-i Glass, Rocky Brands, and other stocks also down in pre-market…
6 months ago benzinga.com
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
8 months ago benzinga.com
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Top analysts upgraded RPM, Dow, Intellia, Sempra, & Target stocks. See ratings & targets. Potential to buy TGT stock, analysts say. Photo via Shutterstock
8 months ago benzinga.com
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19,…
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
-
8 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
10 Health Care Stocks With Whale Alerts In Today's Session
9 months ago benzinga.com
HCA Healthcare Posts Upbeat Q4 Earnings, Joins Redwire, General Motors And Other Big Stocks Moving Higher On Monday
HCA Healthcare Posts Upbeat Q4 Earnings, Joins Redwire, General Motors And Other Big Stocks Moving Higher On Monday
-
9 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
10 Health Care Stocks With Whale Alerts In Today's Session
10 months ago benzinga.com
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
-
10 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
11 months ago benzinga.com
This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session